{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:30:37Z","timestamp":1792740637299,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ebiom.2022.104138","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T21:35:33Z","timestamp":1657143333000},"page":"104138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial"],"prefix":"10.1016","volume":"82","author":[{"given":"Jonathan A.","family":"Robbins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dereck","family":"Tait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinlei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami","family":"Crumley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josee","family":"Cote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5725-558X","authenticated-orcid":false,"given":"Jeffrey R.","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Joseph","family":"Howitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Rondon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Hernandez-Illas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"O'Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Hardalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wnek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alethea","family":"Cope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eseng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Annunziato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalya","family":"Guris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Aubrey","family":"Stoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2022.104138_bib0001","unstructured":"John Hopkins University & Medicine [Webpage]. COVID-19 dashboard by The Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). [Cited November 2021]. Available from: https:\/\/www.coronavirus.jhu.edu\/map.html."},{"issue":"6493","key":"10.1016\/j.ebiom.2022.104138_bib0002","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1126\/science.abb5793","article-title":"Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period","volume":"368","author":"Kissler","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104138_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.35772\/ghm.2021.01010","article-title":"COVID-19 vaccines: implementation, limitations and opportunities","volume":"3","author":"Richman","year":"2021","journal-title":"Global Health Med"},{"issue":"10068","key":"10.1016\/j.ebiom.2022.104138_bib0004","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104138_bib0005","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104138_bib0006","unstructured":"World Health Organization [Webpage]. 10th Ebola outbreak in the Democratic Republic of the Congo declared over; vigilance against flare-ups and support for survivors must continue. 2020 Jun 25 [cited November 2021]. Available from: https:\/\/www.who.int\/news\/item\/25-06-2020-10th-ebola-outbreak-in-the-democratic-republic-of-the-congo-declared-over-vigilance-against-flare-ups-and-support-for-survivors-must-continue."},{"issue":"1","key":"10.1016\/j.ebiom.2022.104138_bib0007","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1038\/s41467-020-20228-7","article-title":"A single dose of recombinant VSV-\u2206G-spike vaccine provides protection against SARS-CoV-2 challenge","volume":"11","author":"Yahalom-Ronen","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2022.104138_bib0008","unstructured":"US National Library of Medicine [Webpage]. ClinicalTrials.gov: Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001) [Cited November 2021]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04569786."},{"key":"10.1016\/j.ebiom.2022.104138_bib0009","unstructured":"US Department of Health and Human Services FaDA. Toxicity Grading Scale for Healthy Adults and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. 2007."},{"key":"10.1016\/j.ebiom.2022.104138_bib0010","first-page":"134","article-title":"Longitudinal data analysis of continuous and discrete responses for pre-post designs","volume":"Series B","author":"Liang","year":"2000","journal-title":"Indian J Statis"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104138_bib0011","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"Philip V'kovski","year":"2021","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104138_bib0012","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.virusres.2004.08.009","article-title":"Rhabdovirus assembly and budding","volume":"106","author":"Himangi","year":"2004","journal-title":"Virus Res"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104138_bib0013","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104138_bib0014","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41591-020-0868-6","article-title":"Barnes & HCA Lung Biological Network. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes","volume":"26","author":"Waradon Sungnak","year":"2020","journal-title":"Nat Med"},{"issue":"385","key":"10.1016\/j.ebiom.2022.104138_bib0015","first-page":"1701","article-title":"Ottenhoff and Claire-Anne Siegrist. A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa","volume":"12","author":"Angela Huttner","year":"2019","journal-title":"Science Transl Med"},{"key":"10.1016\/j.ebiom.2022.104138_bib0016","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3389\/fmicb.2017.01571","article-title":"Ebola virus glycoprotein induces an innate immune response in vivo via TLR4","volume":"8","author":"Lai","year":"2017","journal-title":"Front Microbiol"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104138_bib0017","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.immuni.2019.08.007","article-title":"Immunological Lessons from Respiratory Syncytial Virus Vaccine Development","volume":"51","author":"Ruckwardt","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ebiom.2022.104138_bib0018","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ebiom.2017.03.045","article-title":"Dose-dependent t-cell dynamics and cytokine cascade following rVSV-ZEBOV immunization","volume":"19","author":"Dahlke","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ebiom.2022.104138_bib0019","doi-asserted-by":"crossref","unstructured":"A Largajolli, N Plok, B Kandala, et\u00a0al. Cross-species translation of correlates of protection for COVID-19 vaccine candidates using quantitative tools. Poster (#1010) presented at ID week [virtual]; 2021 Sep 29\u2013Oct 3.","DOI":"10.1093\/ofid\/ofab466.1204"},{"key":"10.1016\/j.ebiom.2022.104138_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","author":"Khoury","year":"2021","journal-title":"Nat Med"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642200319X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642200319X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:19:45Z","timestamp":1762456785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235239642200319X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":20,"alternative-id":["S235239642200319X"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104138","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Merck Sharp & Dohme Corp., a subsidiary Merck & Co., Inc., Kenilworth, NJ, USA and The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104138"}}